Bipartisan congressional lawmakers recently sent a pointed letter to the head of the Food and Drug Administration (FDA), complaining about the “completely insufficient response” the agency provided in response to their bill calling for hemp-derived CBD to be permitted and regulated as a food additive.
After the CBD Product Safety and Standardization Act was filed in December 2021, the sponsors sought technical assistance from FDA to advise on key provisions. But four months after they sent the inquiry, FDA returned a “one-page” response that was “simply a reformatting of a document provided to Congress over two years ago,” the lawmakers said late last month in a letter that was released on Wednesday.
FDA’s response “does not address provisions of our bill drafted specifically to address product safety, and is a completely insufficient response at this moment when cannabidiol (CBD) products are proliferating around the country,” Reps. Kathleen Rice (D-NY), Morgan Griffith (R-VA), Angie Craig (D-MN) and Dan Crenshaw (R-TX) wrote.
Despite being given regulatory authority over hemp and its derivatives under the 2018 Farm Bill, “FDA has refused to act on that authority, allowing a marketplace where dangerous products, like those containing delta-8 THC, are often indistinguishable from products that
Read full article on Marijuana Moment
